(2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxo-propan-2-amine | 312639-10-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxo-propan-2-amine
• 英文别名: 2-(R)-amino-3-(4-chlorophenyl)-1-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)propan-1-one；(2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-piperidin-1-yl]-1-oxopropan-2-amine；(2R)-2-amino-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1,2,4-triazol-1-ylmethyl)piperidin-1-yl]propan-1-one
• CAS: 312639-10-4
• 化学式: C₂₃H₃₂ClN₅O
• 分子量: 429.993
• InChiKey: VADQRJNCGGKONM-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  77
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxo-propan-2-amine 在 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成 3-Amino-N-[(R)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propionamide
  参考文献：
  名称：

  β-Alanine dipeptides as MC4R agonists

  摘要：

  beta-Alanine derivative 2 (IC50 = 16 nM) and related compounds were found to be potent MC4R agonists. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.036
• 作为产物：
  描述：

  去甲哌替啶 在 Rh/Al₂O₃ N-甲基吗啉 、 盐酸 、 lithium aluminium tetrahydride 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxo-propan-2-amine
  参考文献：
  名称：

  Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist

  摘要：

  Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development-of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

  DOI：

  10.1021/jm025539h

文献信息

• OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Braun Alain

  公开号：US20070149562A1

  公开（公告）日：2007-06-28

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及根据本文所定义的式（I）的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗或预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。
• Melanocortin receptor ligands
  申请人：——

  公开号：US20040010010A1

  公开（公告）日：2004-01-15

  The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: 1 wherein preferably R is substituted aryl, W 1 is a carbocyclic unit, and W 2 is a heteroatom comprising unit.

  本发明涉及包含一个与取代或未取代的烃基环相连的4-取代哌啶环的化合物。这些化合物，包括所有的对映异构体和二对映异构体形式以及其药用盐，具有以下公式：其中R最好是取代芳基，W1是一个碳环单元，W2是一个含有杂原子的单元。
• [EN] CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS<br/>[FR] COMPOSES GLUTARAMIDE A SUBSTITUTION CYCLOPENTILE UTILISES COMME INHIBITEURS DE L'ENDOPEPTIDASE
  申请人：PFIZER LTD

  公开号：WO2004056750A1

  公开（公告）日：2004-07-08

  The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R1 is C,-C6alkyl, Ci-C6alkoxyC,­C3alkyl or C,-C6alkoxyC,-C6alkoxyC,-C3alkyl; R2 is hydrogen or C,-C6alkyl; L is a three 5 atom linkage selected from -CH2-X-CH2- and -CH2-CH2-X- where the right hand side of the linkage is attached to R3 and where X is oxygen, sulfur or methylene; R3 is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C1-C6alkyl, halo, haloC,-C6alkyl, C,-C6alkoxy, haloC1-C6alkoxy, C1-­C6alkylthio, haloC,-C6alkylthio and nitrile; and R4 and R5 are either both hydrogen, or one of R4 and R5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

  该发明涉及NEP抑制剂用于治疗心血管疾病。首选的NEP抑制剂是具有以下结构的化合物(I)：其中R1为C1-C6烷基，C1-C6烷氧基C1-C3烷基或C1-C6烷氧基C1-C6烷氧基C1-C3烷基；R2为氢或C1-C6烷基；L为从-CH2-X-CH2-和-CH2-CH2-X-中选择的三个原子连接，其中连接的右侧连接到R3，X为氧、硫或亚甲基；R3为苯基或芳香杂环基，两者中的任何一个都可以独立地被一个或多个来自以下群的基取代：C1-C6烷基，卤素，卤代C1-C6烷基，C1-C6烷氧基，卤代C1-C6烷氧基，C1-C6烷基硫基，卤代C1-C6烷基硫基和腈基；R4和R5要么都是氢，要么R4和R5中的一个是氢，另一个是在患者体内被氢替代的生物可解脂基。
• Chiral Effect of a Phe Residue in Position 3 of the Dmt¹-<scp>l</scp>(or <scp>d</scp>)-Tic² Analogues on Opioid Functional Activities
  作者：Yeon Sun Lee、HongChang Qu、Peg Davis、Shou-Wu Ma、Ruben Vardanyan、Josephine Lai、Frank Porreca、Victor J. Hruby

  DOI：10.1021/ml400115n

  日期：2013.7.11

  In this letter, we describe a structure-activity relationships study, specifically related to the chirality of third amino acid residue in our H-Dmt-L(or D)-Tic analogues, of which C-terminus is attached to a piperidinyl moiety. Observed selectivities and functional activities of these analogues demonstrated that the chiralities of the second and third position residues are crucial for determining whether these ligands act as antagonists or agonists at the delta opioid receptor, but not at the mu opioid receptor.
• N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FEEDING DISORDERS
  申请人：The Procter & Gamble Company

  公开号：EP1499314A1

  公开（公告）日：2005-01-26